Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Tianjin Development Holdings ( (HK:0882) ) has provided an update.
Tianjin Development Holdings Limited announced the unaudited financial results for its subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., for the first quarter of 2025. Lisheng Pharmaceutical reported a slight increase in total operating income to RMB 369.84 million, with a net profit of RMB 56.57 million. The results indicate stable performance with a focus on managing operating costs and enhancing research and administrative expenses, reflecting the company’s strategic efforts to maintain its market position.
More about Tianjin Development Holdings
Tianjin Development Holdings Limited operates in the pharmaceutical industry through its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. Lisheng Pharmaceutical, a company incorporated in China and listed on the Shenzhen Stock Exchange, focuses on the production and sale of pharmaceutical products.
For detailed information about 0882 stock, go to TipRanks’ Stock Analysis page.